Inpatient Expenditures Attributable to Hospital-Onset Clostridium difficile Infection: A Nationwide Case–Control Study in Japan
Hospital-onset Clostridium difficile infections (CDIs) have a considerable clinical and economic impact on patients and payers. Quantifying the economic impact of CDIs can guide treatment strategies. However, previous studies have generally focused on acute care hospitals, and few have included cost estimates from non-acute care hospitals such as long-term care facilities.
This study aimed to quantify the hospital-onset CDI-attributable inpatient expenditures and length-of-stay durations in all healthcare institutions that provide inpatient care (including acute and non-acute care) in Japan.
Using national-level insurance claims data, we analyzed patients who had been hospitalized between April 2010 and December 2016. CDI cases were identified and matched with non-CDI controls using hospitalization year, treating hospital, age, sex, surgical procedure, comorbidities, and main diagnoses. Through multivariable regression analyses, we estimated the CDI-attributable inpatient expenditures (2016 US dollars) and length-of-stay durations (days) while adjusting for variations in factors such as patient characteristics, comorbidities, surgery, prescribed antibiotic, geographic region, and hospitalization year. We also analyzed the CDI-attributable inpatient expenditures and length-of-stay durations according to hospital type (acute care and rehabilitation/long-term care).
The analysis was conducted using 3768 matched pairs. Overall, CDI-attributable inpatient expenditures and length-of-stay durations were US$3213 and 11.96 days, respectively. Rehabilitation/long-term care hospitals had substantially higher inpatient expenditures and longer hospitalizations than acute care hospitals.
This study quantified the hospital-onset CDI-attributable inpatient expenditures and hospitalizations in both acute and non-acute care hospitals. The inclusion of non-acute care hospitals provides a more accurate representation of the economic burden of CDIs.
We are grateful to Mr S. Kondo and Mr S. Yamakawa from Denno Labo Corporation for their support in extracting the study sample from the National Database (NDB).
Haruhisa Fukuda, Takahisa Yano, and Nobuyuki Shimono contributed to the study’s conception and design. Haruhisa Fukuda carried out the analysis of the data and drafted the manuscript. All authors were involved in the interpretation of the results, as well as in the editing and revision of the manuscript.
Compliance with Ethical Standards
Source of Funding
This work was supported by a Grant-in-Aid for Health Sciences Research by the Ministry of Health, Labor and Welfare of Japan (Grant Number: H29-Seisaku-Shitei-010) and a KAKENHI Grant-in-Aid for Scientific Research by the Japan Society for the Promotion of Science (Grant Number: JP17H04144).
Conflict of Interest
Haruhisa Fukuda, Takahisa Yano, and Nobuyuki Shimono declare that they have no conflicts of interest, financial or otherwise.
- 2.Honda H, Dubberke E, Fukuda T, Senoh M, Reske K, Olsen M, et al. Epidemiology of Clostridium difficile infections in Japan. IDWeek 2016; New Orleans October 26–30.Google Scholar
- 10.Magee G, Strauss ME, Thomas SM, Brown H, Baumer D, Broderick KC. Impact of Clostridium difficile-associated diarrhea on acute care length of stay, hospital costs, and readmission: a multicenter retrospective study of inpatients, 2009-2011. Am J Infect Control. 2015;43(11):1148–53.CrossRefGoogle Scholar
- 16.Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.CrossRefGoogle Scholar
- 20.Williams R. Using the margins command to estimate and interpret adjusted predictions and marginal effects. Stata J. 2012;12:308–31.Google Scholar